1. Home
  2. BAK vs NGNE Comparison

BAK vs NGNE Comparison

Compare BAK & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Braskem SA ADR

BAK

Braskem SA ADR

HOLD

Current Price

$1.96

Market Cap

900.6M

Sector

Industrials

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$38.63

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAK
NGNE
Founded
1972
2003
Country
Brazil
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
900.6M
744.9M
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
BAK
NGNE
Price
$1.96
$38.63
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$4.40
$63.57
AVG Volume (30 Days)
1.8M
156.3K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.93
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.02
N/A
Revenue Next Year
$7.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$15.93
52 Week High
$5.40
$43.66

Technical Indicators

Market Signals
Indicator
BAK
NGNE
Relative Strength Index (RSI) 32.95 58.03
Support Level $1.83 $18.24
Resistance Level $3.17 $43.66
Average True Range (ATR) 0.15 2.26
MACD -0.00 0.24
Stochastic Oscillator 17.47 78.87

Price Performance

Historical Comparison
BAK
NGNE

About BAK Braskem SA ADR

Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: